CliffBio
small molecule

CUVRIOR

TRIENTINE TETRAHYDROCHLORIDE

Loss of exclusivityMay 2039latest FDA-listed patent expiry
CompanyORPHALAN SA

Drug detail

Brand nameCUVRIOR
Active ingredientTRIENTINE TETRAHYDROCHLORIDE
Strength300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

Listed patents

PatentExpiresType
12358862May 2039substance, product
12358861May 2039substance, product
11072577May 2039use U-3370
12662445May 2039substance, product
10988436May 2039substance

Regulatory exclusivity

CodeExpires
ODE-401April 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CUVRIOR patent cliff — loss of exclusivity May 2039 | CliffBio